MS Drug Tysabri (Natalizumab) Poses Hard Choices for Women Wanting Children

THURSDAY, Feb. 8, 2018 -- A powerful multiple sclerosis drug presents women with a tough dilemma if they would like to have children, a pair of new studies suggests. Those who take Tysabri (natalizumab) to manage their MS are more likely to suffer...
Source: - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

This article presents the consensus of Belgian MS specialists and nephrologists on the practicalities of diagnosis, management, and treatment of alemtuzumab-associated ren al adverse events based on good clinical practice.
Source: Acta Neurologica Belgica - Category: Neurology Source Type: research
In conclusion, the findings suggested that CR seems to mitigate cognitive dysfunction in MS patients and can reduce the negative impact of brain atrophy on inhibitory control, relevant for integrity of instrumental activities of daily living.
Source: Journal of Neurology - Category: Neurology Source Type: research
Publication date: 15 July 2018 Source:Neuroscience, Volume 383 Author(s): Liam E. Potter, Suzanne Doolen, Katherine Mifflin, Gustavo Tenorio, Glen Baker, Bradley K. Taylor, Bradley J. Kerr The putative strong anti-nociceptive properties of the antidepressant phenelzine (PLZ) have not been widely explored as a treatment for pain. Antinociceptive effects of PLZ were identified in the formalin model of tonic pain (Mifflin et al., 2016) and in allodynia associated with experimental autoimmune encephalomyelitis, (EAE) a mouse model of multiple sclerosis (Potter et al., 2016). Here, we further clarify the specific types of stim...
Source: Neuroscience - Category: Neuroscience Source Type: research
Publication date: June 2018 Source:The Journal of Steroid Biochemistry and Molecular Biology, Volume 180 Author(s): Andreia Bettencourt, Daniela Boleixa, Henrique Reguengo, Raquel Samões, Ernestina Santos, José Carlos Oliveira, Berta Silva, Paulo Pinho Costa, Ana Martins da Silva Increasing evidence has shown that individuals with Multiple Sclerosis (MS) have lower 25-hydroxyvitamin D [25(OH)D] levels compared to healthy controls. There is no information regarding 25(OH)D levels and MS in Portugal. Therefore the aim of the current study was to examine the levels of 25(OH)D in a group of patients with MS and ...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Publication date: Available online 25 May 2018 Source:Multiple Sclerosis and Related Disorders Author(s): RM Middleton, WJ Rodgers, J Chataway, K Schmierer, D Rog, I Galea, A Akbari, K Tuite-Dalton, H Lockhart-Jones, D Griffiths, DG Noble, KH Jones, A Al-Din, M Craner, N Evangelou, P Harman, T Harrower, J Hobart, H Husseyin, M Kasti, C Kipps, G McDonnell, C Owen, O Pearson, W Rashid, H Wilson, DV Ford The UK Multiple Sclerosis Register (UKMSR) is a large cohort study designed to capture ‘real world’ information about living with multiple sclerosis (MS) in the UK from diverse sources. The primary source of data...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Acta Neurologica Scandinavica, EarlyView.
Source: Acta Neurologica Scandinavica - Category: Neurology Authors: Source Type: research
Publication date: August 2018 Source:Biomedicine & Pharmacotherapy, Volume 104 Author(s): Sanam Dolati, Faroogh Marofi, Zohreh Babaloo, Leili Aghebati-Maleki, Leila Roshangar, Majid Ahmadi, Reza Rikhtegar, Mehdi Yousefi Multiple sclerosis (MS) is a chronic and organ-specific autoimmune disease in which immune cells act against the myelin sheath, resulting in central nervous system (CNS) damage. It has been revealed that miRNAs can play significant role in the pathogenesis of MS. These regulatory molecules lead to the activation of different signaling pathways, regulation of several transcriptional factors, influencing...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: August 2018 Source:Biomedicine & Pharmacotherapy, Volume 104 Author(s): Jelena Jakovljevic, C. Randall Harrell, Crissy Fellabaum, Aleksandar Arsenijevic, Nemanja Jovicic, Vladislav Volarevic Due to their trophic and immunoregulatory characteristics mesenchymal stem cells (MSCs) have tremendous potential for use in a variety of clinical applications. Challenges in MSCs’ clinical applications include low survival of transplanted cells and low grafting efficiency requiring use of a high number of MSCs to achieve therapeutic benefits. Accordingly, new approaches are urgently needed in order to over...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
This scientific commentary refers to ‘Progression of regional grey matter atrophy in multiple sclerosis’, by Eshagiet al. (doi:10.1093/brain/awy088).
Source: Brain - Category: Neurology Source Type: research
Conditions:   Multiple Sclerosis;   Gait Disorders, Neurologic;   Cognitive Impairment Interventions:   Other: Dual-task gait;   Other: Single-task gait Sponsors:   Texas Woman's University;   TIRR Memorial Hermann;   The University of Texas Health Science Center, Houston Recruiting
Source: - Category: Research Source Type: clinical trials
More News: Children | General Medicine | Multiple Sclerosis | Study | Tysabri | Women